IDT Biologika and Exothera Collaborate on Scaling Up Viral Vaccines
IDT Biologika, a Germany-based CDMO specializing in vaccines, gene and immune therapy, and oncolytic viruses, and Exothera, a CDMO in Belgium, agreed to collaborate on the development of a large-scale manufacturing process for viral vector-based vaccines. The feasibility study is focussing on Modified Vaccinia Ankara (MVA) virus as a first example for IDT’s range of vector technologies.
Exothera reports that it has successfully transferred IDT Biologika’s upstream process from small- to large-scale using the NevoLine™ upstream platform developed by Univercells Technologies. The NevoLine system incorporates the scale-X™ structured fixed-bed bioreactor system, which offers a range of options to scale viral production from R&D to commercialization, according to Exothera.
The collaboration between IDT and Exothera is designed to demonstrate the application and increased performance of the NevoLine platform at full commercial capacity.
Please, to access the full article visit GEN